Apellis Pharmaceuticals (APLS) as of March 31, 2026 presents a materially negative liquidation recovery to equity under a stop-and-liquidate scenario. Total book assets of $1.08B face significant haircuts: cash and equivalents of $405M recover at par; gross AR of $440M recovers at approximately $418M (95%); inventory of $160M (current $131M plus noncurrent $28M) recovers at roughly $96M (60%), though the inventory pool contains $16.8M of pre-FDA-approval material with uncertain liquidation value and a $20M write-down already charged in the current period signals ongoing obsolescence risk; PP&E net of $1.4M recovers at roughly $0.7-1.0M; operating lease ROU asset of $18.9M receives 0% recovery as an intangible use right; other noncurrent assets of $5.7M are largely non-recoverable. Haircutted asset total approximates $930-935M. On the liability side, at full face value: current liabilities of $283M (including $94M of Convertible Notes due within 12 months, $134M accrued liabilities, $49M AP, $11M accrued royalties, $7M current operating lease); long-term Sixth Street credit facility of $362M (drawn $375M original, now $362M carrying value net of OID); noncurrent operating lease of $13M; other noncurrent liabilities of $9M; total liabilities at face approximately $668M. Rough liquidation residual: ~$930M haircutted assets minus $668M face liabilities = approximately $262M gross recovery, well below the $415M book equity. However, this does not account for wind-down costs, contractual purchase commitments ($6.4M disclosed), or the Sixth Street credit facility's prepayment provisions and potential exit fees. The operating cash burn was $61M in Q1 2026 despite first quarterly GAAP net income of $18.7M, driven by a $74M AR build and working capital outflows. The most significant structural change since the prior 10-K filing (December 31, 2025): on March 31, 2026, Apellis entered into a Merger Agreement with Biogen Inc. at $41.00/share cash plus contingent value rights of up to $4.00/share tied to SYFOVRE net sales milestones. This pending transaction fundamentally changes the liquidation lens context—if completed, equity recovers at the Merger price; if terminated, APLS bears a $205M termination fee payable to Biogen, which at current cash levels ($405M) would consume approximately 51% of unrestricted cash. The Convertible Notes of $93.7M mature September 2026, requiring near-term refinancing or repayment absent the Merger closing. Filing discusses the Royalty Agreement and the Sobi Collaboration Agreement generating one-time milestones of $55M in Q1 2026 in MD&A but these are revenue items, not balance sheet recoverable assets.
▼ Community Notes